DOI,title,author,year,times_seen
10.1128/aac.46.1.69-74.2002,"Pharmacodynamics of Gatifloxacin against
            <i>Streptococcus pneumoniae</i>
            in an In Vitro Pharmacokinetic Model: Impact of Area under the Curve/MIC Ratios on Eradication",Lister,2002,1
10.1128/aac.37.5.1073,Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients,Forrest,2012,1
10.1128/aac.41.7.1594,"In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis",Brueggemann,2018,1
10.1016/j.ejps.2021.105868,Population pharmacokinetics-pharmacodynamics of ceftazidime in neonates and young infants: Dosing optimization for neonatal sepsis,Li,2021,1
10.1055/s-0034-1398490,Applying Pharmacokinetic/Pharmacodynamic Principles in Critically Ill Patients: Optimizing Efficacy and Reducing Resistance Development,Abdul-Aziz,2015,1
10.1097/pcc.0000000000000225,Pediatric Severe Sepsis in U.S. Childrenâ€™s Hospitals*,Balamuth,2014,1
10.1016/j.mib.2013.06.010,PK/PD models in antibacterial development,Velkov,2013,1
